Pricey Drug Combo Boosts PFS in First-Line Advanced Ovarian Cancer

(MedPage Today) -- CHICAGO -- A three-drug combination significantly improved progression-free survival (PFS) in newly diagnosed non-BRCA advanced ovarian cancer but raised questions about the cost of the regimen, according to a study reported...
Source: MedPage Today Public Health - Category: American Health Source Type: news